Bernie Sunwoo, MD
Pulmonary Disease · San Diego, CANPI 1336294107
Payments from drug & device makers
Across 8 payments — averaging $26,602 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Jazz Pharmaceuticals Inc.$213K
- Eisai Inc.$125
- Philips North America LLC$74
What the payments were for
- Food & beverage$199100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Jazz Pharmaceuticals Inc. | 6 | $212,616 |
| Eisai Inc. | 1 | $125 |
| Philips North America LLC | 1 | $74 |
How this compares
$212,815 in reported general payments places this provider in the 90th percentile of 1,261 pulmonary disease providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 25 | $276,135 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 76 | $55,733 |
| Spiriva RespimatTiotropium Bromide | 74 | $47,665 |
| Dupixent PenDupilumab | 11 | $37,849 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 33 | $21,809 |
| SymbicortBudesonide/Formoterol Fumarate | 62 | $19,039 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 26 | $13,554 |
| Incruse ElliptaUmeclidinium Bromide | 17 | $13,230 |
| DuleraMometasone/Formoterol | 29 | $11,355 |
| Breo ElliptaFluticasone/Vilanterol | 19 | $8,864 |
| Fluticasone Propionate HfaFluticasone Propionate | 16 | $5,059 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 112 | $4,909 |
| BreynaBudesonide/Formoterol Fumarate | 21 | $4,297 |
| Sirolimus | 12 | $3,766 |
| Wixela InhubFluticasone Propion/Salmeterol | 21 | $2,997 |
Paid to pharmacies, not to this prescriber.
Other pulmonary disease in San Diego
- Edward FedermanSan Diego$3.6M
- David PochSan Diego$1.5M
- Shari BrazinskySan Diego$522K
- Samir MakaniSan Diego$371K
- George ChengSan Diego$309K
- Toby MaherLos Angeles$27.6M
- David PhamWestminster$5.9M
- Andrew WachtelLos Angeles$5.9M
- Aaron WeinbergIrvine$5.1M
- Michael RothLos Angeles$4.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.